Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer
17. juni 2026 oppdatert av: Jiuda Zhao, Affiliated Hospital of Qinghai University
Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer: A Randomized Controlled Clinical Trial
This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with early stage cancer.
At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.
Studieoversikt
Status
Har ikke rekruttert ennå
Intervensjon / Behandling
Detaljert beskrivelse
A prospective, multicenter, block-randomized, blinded study design will be adopted.
The study will screen patients with early stage breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer, and ovarian cancer who are receiving chemotherapy.
Eligible participants will be randomly assigned in a 1:1 ratio, through a screening and informed consent process, to either the experimental group or the control group.
The experimental group will receive electroacupuncture combined with thumbtack needle treatment, while the control group will receive sham electroacupuncture combined with sham thumbtack needle treatment.
The primary endpoint will be the incidence of CIPN during chemotherapy(assessed by NCI-CTCAE).
Secondary endpoints will include: the incidence of CIPN at 3, 6, and 9 months after the start of chemotherapy; the incidence of ≥ grade 3 sensory CIPN within 3, 6, 9, and 12 months after the start of chemotherapy; and the incidence of ≥ grade 2 sensory CIPN within 3, 6, 9, and 12 months after the start of chemotherapy.
Simultaneously evaluate the safety of treatment and the quality of life of patients.
Changes in nerve conduction velocity will be detected before the first cycle of chemotherapy and after the fourth cycle of chemotherapy.
Studietype
Intervensjonell
Registrering (Antatt)
278
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Jiuda Zhao
- Telefonnummer: 869716162732
- E-post: jiudazhao@126.com
Studer Kontakt Backup
- Navn: Fuxing Zhao
- Telefonnummer: 18797349621
- E-post: 18797349621@163.com
Studiesteder
-
-
Qinghai
-
Xining, Qinghai, Kina, 810000
- Qinghai University Affiliated Hospital
-
Ta kontakt med:
- Jiuda Zhao
- Telefonnummer: 869716162732
- E-post: jiudazhao@126.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years.
- Pathological and imaging examinations confirmed the diagnosis of early-stage cancer(I-III stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer.
- Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. Non small cell lung cancer or Ovarian cancer: Taxane-containing regimen.
- No history of acupuncture treatment within one month prior to study initiation.
- Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10^9/L; Platelet count ≥ 100 × 10^9/L; White blood cell count 3.5 - 9.5 × 10^9/L; Hemoglobin ≥ 100 g/L. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal; Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration < 1.5 mg/dL; Serum albumin > 2.5 g/dL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL/min (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.
- Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.
- Voluntarily agree to participate in the study and sign an informed consent form.
Exclusion Criteria:
- Patients with advanced cancer.
- Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.
- Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.
- Presence of active skin infection or other conditions unsuitable for acupuncture treatment.
- Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.
- Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).
- Pregnant or lactating patients.
- Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.
- Patients with active brain metastases.
- Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: True electroacupuncture combined with true thumbtack needle group
Electroacupuncture will be administered on days 1, 2 and 3 of chemotherapy, followed by thumbtack needle therapy on days 4, 5, and 6 of chemotherapy, and no intervention will be given at other times.
For electroacupuncture, we will choose the following acupoints: Zusanli, Hegu, Taichong, Quchi, and Yanglingquan.
After achieving 'deqi', electrodes will be connected bilaterally as follows: Quchi to Yanglingquan, and Hegu to Zusanli.
Stimulation will be delivered at 2/10Hz with a current of ≤10mA for 30 minutes.
For thumbtack needle therapy, bilateral Zusanli, Hegu, and Taichong points will be sterilized with 75% alcohol before inserting and embedding the thumbtack needles.
On the day of thumbtack needle therapy, patients will be instructed to press each thumbtack for one minute at 9:00, 13:00, and 17:00, to induce a mild sensation of soreness and fullness.
The electroacupuncture and thumbtack needle therapy will be given for each chemotherapy cycle.
|
The acupoints Zusanli, Hegu, Taichong, Quchi, and Yanglingquan will be selected for treatment.
After inserting the needle with a 'deqi', electrodes will be connected bilaterally as follows: Quchi to Yanglingquan, and Hegu to Zusanli.
The electroacupuncture parameters adopt a sparse wave type, with a frequency of 2/10Hz and a current intensity not exceeding 10mA.
The treatment time is 30 minutes, based on the patient's tolerance.
The Zusanli, Hegu, and Taichong on both sides will be selected for thumbtack needle therapy, clean the skin with a 75% alcohol cotton swab, and quickly insert the thumbtack needle into the skin and into the selected acupoints.
At 9:00, 13:00, 17:00, and 21:00, patients will be instructed to press each acupoint for one minute, with pressure adjusted to a tolerable level of mild pain or achin.
If fainting or skin allergies occur during the thumbtack needle therapy, the thumbtack needle will be promptly removed.
|
|
Sham-komparator: Sham electroacupuncture combined with sham thumbtack needle group
Sham electroacupuncture will be administered on days 1, 2, and 3 of chemotherapy, followed by sham thumbtack needle therapy on days 4, 5, and 6 of chemotherapy, and no intervention will be given at other times.
Sham electroacupuncture operation: Select the same acupoints as the experimental group, select 1-2cm near the Zusanli, Hegu, Taichong, Quchi, and Yanglingquan acupoints, shallow subcutaneous puncture, no electricity, 30 minutes.
Sham thumbtack needle operation: Select 1-2cm near the Zusanli, Hegu, and Taichong acupoints on both sides to apply fake snap needles(remove the needle tip) without pressing.
The same sham electroacupuncture and sham thumbtack needle therapy will be given for each chemotherapy cycle.
|
Select Zusanli, Hegu, Taichong, Quchi, and Yanglingquan on both sides will be selected for sham electroacupuncture therapy, select 1-2cm near the Zusanli, Hegu, Taichong, Quchi, and Yanglingquan acupoints, shallow subcutaneous puncture, no electricity, 30 minutes.
Select Zusanli, Hegu, and Taichong on both sides will be selected for sham thumbtack needle therapy.
Select 1-2cm near the Zusanli, Hegu, and Taichong acupoints on both sides and apply sham thumbtack needle (remove the needle tip) without pressing.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The incidence of CIPN during chemotherapy (from the beginning of chemotherapy to the end of chemotherapy for any reason) .
Tidsramme: 1 year
|
The number of cases of CIPN occurring during chemotherapy/Total number of cases
|
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The incidence of CIPN at 3, 6, 9, and 12 months after the start of chemotherapy
Tidsramme: 1 year
|
Number of CIPN cases at 3, 6, 9, and 12 months after the start of chemotherapy/Total number of cases
|
1 year
|
|
The incidence of ≥ grade 3 sensory CIPN at 3, 6, 9, and 12 months after the start of chemotherapy
Tidsramme: 1 year
|
Number of cases of ≥ grade 3 sensory CIPN occurring at 3, 6, 9, and 12 months after the start of chemotherapy/Total number of cases
|
1 year
|
|
The incidence of ≥ grade 2 sensory CIPN at 3, 6, 9, and 12 months after the start of chemotherapy
Tidsramme: 1 year
|
Number of cases of ≥ grade 2 sensory CIPN occurring at 3, 6, 9, and 12 months after the start of chemotherapy/Total number of cases
|
1 year
|
|
The time of occurrence of all levels and levels 3 and above CIPN
Tidsramme: 1 year
|
The time of occurrence of all levels and levels 3 and above CIPN
|
1 year
|
|
EORTC-CIPN20 evaluation score
Tidsramme: 1 year
|
The scale consists of 20 questions, each divided into 4 levels: 1 point: completely none, 2 points: a little, 3 points: quite a lot, 4 points: very much.
The total score is converted into a standard rating score (0-100 points) through linear conversion.
|
1 year
|
|
EQ-5D-5L evaluation score
Tidsramme: 1 year
|
For the Descriptive System(Health State Index): A single summary index value(often called a 'utility' score) is calculated by applying a country-specific or region-specific value set(or 'tariff') to the 5-digit health state code.
These value sets, derived from general population studies, assign weights to each possible health state.
The index typically ranges from values less than 0(where 0=dead, and states worse than dead have negative values) to 1(full health).
There is no single global scoring formula; the appropriate national value set must be used.
For the EQ VAS: The score is the self-reported number between 0 and 100, representing the respondent's perception of their overall health at that moment.
It is reported as a raw score.
|
1 year
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
25. mai 2026
Primær fullføring (Antatt)
25. mai 2029
Studiet fullført (Antatt)
31. juli 2029
Datoer for studieregistrering
Først innsendt
15. februar 2026
Først innsendt som oppfylte QC-kriteriene
17. juni 2026
Først lagt ut (Faktiske)
23. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
23. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
17. juni 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- AHQU-2026001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .